Skip to main content

Table 3 Correlation of EVI1 expression with therapy response and clinical outcomes among BC subtypes

From: EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy

BC subtype

EVI1

pCR (ypT0 ypN0)

DFS

OS

Odds ratio

(95% CI)

p-value*

Int. p-value

Hazard ratio

(95% CI)

p-value*

Int. p-value

Hazard ratio

(95% CI)

p-value*

Int. p-value

HR + /HER2-

continuous

1.18

(0.56–2.50)

0.666

0.555

1.11

(0.73–1.70)

0.617

0.140

1.00

(0.59–1.69)

0.988

0.304

HR + /HER2 + 

continuous

0.81

(0.32–2.05)

0.662

 

0.87

(0.52–1.45)

0.581

 

0.76

(0.40–1.46)

0.411

 

HR-/HER2 + 

continuous

1.52

(0.53–4.41)

0.440

 

0.81

(0.40–1.65)

0.562

 

0.62

(0.29–1.34)

0.226

 

TNBC

continuous

1.41

(0.79–2.52)

0.249

 

0.75

(0.50–1.13)

0.165

 

0.74

(0.47–1.18)

0.204

 

HR + /HER2-

EVI1 high vs low

1.01

(0.51–2.01)

0.968

0.283

1.01

(0.69–1.48)

0.961

0.274

1.00

(0.61–1.64)

0.992

0.290

HR + /HER2 + 

EVI1 high vs low

0.96

(0.33–2.75)

0.376

 

0.98

(0.54–1.79)

0.960

 

0.81

(0.37–1.78)

0.602

 

HR-/HER2 + 

EVI1 high vs low

1.32

(0.52–3.35)

0.566

 

0.93

(0.46–1.91)

0.849

 

0.67

(0.27–1.63)

0.370

 

TNBC

EVI1 high vs low

1.60

(0.90–2.85)

0.110

 

0.77

(0.48–1.23)

0.271

 

0.76

(0.44–1.31)

0.314

 
  1. Note, for regression analyses EVI1 continuous expression was transformed at units log10 increase
  2. Int Interaction, CI Confidence interval, HR Hormone receptor, HER2 Human epidermal growth factor receptor 2, TNBC Triple-negative breast cancer
  3. * for EVI1 as continuous variable p-values according to regression logistic (pCR) and Cox (DFS and OS) analyses, for EVI1 as dichotomized variable according to regression logistic (pCR) analysis and log-rank test (DFS and OS)